Across TCGA pan-cancer cohorts, ARHGEF15 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARHGEF15 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ARHGEF15 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ARHGEF15 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC, HNSC, and LSCC are the cancer types where ARHGEF15 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.953	0.646	.004	20	view →
HNSC	DFS	Median	II,III,IV	0.468	0.804	.008	10	view →
LSCC	DFS	Median	All	0.599	0.908	.014	8	view →
LUAD	DFS	Median	II,III,IV	0.743	0.917	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ARHGEF15 tumor-vs-normal RNA expression · all ARHGEF15 data types